Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESd in Relapsed Refractory Multiple Myeloma
NCT05170789Phase 2Withdrawn
- Sponsor
- Tulane University
- Start
- Apr 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Tulane University. Planned start Apr 2022; status: withdrawn.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05170789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170789.